[Clinical evaluation of latamoxef in perinatal infections].
Latamoxef (LMOX) is a new oxacephem antibiotic with a broad spectrum of antimicrobial activity. In vivo transfer and therapeutic efficiency of this drug have studied in perinatal field. The following results have been obtained. Transfer of this drug to umbilical blood was higher than its MIC against majority of Gram-negative pathogens. In the treatment of 5 cases of perinatal infection, the preparation showed excellent efficiency in 2 cases and good efficiency in 3 cases. No side effect was evidenced in any of our patients. In conclusion this drug has satisfactory fetal transfer as well as sufficient safety and excellent efficiency in treatment of perinatal infection cases.
D000328:Adult; D004341:Drug Evaluation; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D005312:Fetal Blood / Q000032:analysis; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D009070:Moxalactam / Q000378:metabolism / Q000627:therapeutic use*; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy*; D011704:Pyelonephritis / Q000188:drug therapy
D009070:Moxalactam